An interventional study of Autologous Platelet Rich Plasma and saline solution (placebo) in Erectile Dysfunction Following Radical Prostatectomy and Erectile Dysfunction, sponsored by Herlev and Gentofte Hospital. Recruiting at 1 site in Denmark. Open to male participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by Herlev and Gentofte Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Erectile Dysfunction with a site in Denmark — 2 open to participants now, 3 under way, none of them phase 3. Erectile Dysfunction · Denmark.
Among the 18 studies in Erectile Dysfunction with a site in Denmark, this one is the 4th largest by planned enrollment of the 14 interventional ones that give a count, is the only one that started in 2026, is one of 9 with no phase, and was the 18th registered.
702 studies on the registry are indexed under Erectile Dysfunction; 125 are open to participants now.
Browse Erectile Dysfunction studies →2 of the 18 studies in Erectile Dysfunction with a site in Denmark are open now. Recruiting first, the newest first:
Herlev and Gentofte Hospital · Sites in Denmark
Ages 18+ · Men only
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 78 Erectile Dysfunction studies recruiting now, 31 (40%) set no upper age limit and 34 (44%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.
This study: 40 Years to 75 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 70 across 551 interventional studies indexed under Erectile Dysfunction.
Median enrollment 90 across the 14 interventional studies, 298 across the 4 observational. Of the 13 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 18 have an industry lead sponsor. The 10 most frequent:
Herlev and Gentofte Hospital is the lead sponsor of 75 studies on the registry; 25 are open to participants now.
Herlev and Gentofte Hospital has 5 studies filed under Erectile Dysfunction — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 18 studies in Erectile Dysfunction with a site in Denmark, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will test whether injections of platelet-rich plasma (PRP) can improve erectile function in men with persistent erectile dysfunction (ED) at least 12 months after nerve-sparing radical prostatectomy for prostate cancer. Participants will be randomly assigned to receive either two PRP injections or two saline (placebo) injections into the penis, administered one month apart in a double-blind fashion. Erectile function will be assessed using the International Index of Erectile Function (IIEF) questionnaire at baseline and at 1, 3, 6, and 12 months after the last injection. The primary objective is to determine whether PRP improves the erectile function domain of the IIEF more than saline at one month after the last injection
Erectile dysfunction is common after nerve-sparing radical prostatectomy and may persist despite recovery from the initial nerve injury. Platelet-rich plasma (PRP) is prepared from autologous blood and contains growth factors that may promote angiogenesis and tissue regeneration. Preclinical studies suggest that PRP may improve erectile function after cavernous nerve injury, but PRP remains an experimental treatment, and no published study has specifically evaluated its effect in men with erectile dysfunction following radical prostatectomy.
The hypothesis is that intracavernosal PRP injections improve erectile function more than saline injections in men with erectile dysfunction persisting 1-3 years after nerve-sparing radical prostatectomy.
Eligible participants will be stratified according to unilateral or bilateral nerve-sparing surgery and randomized 1:1 to receive two intracavernosal injections of either autologous PRP or saline, administered one month apart. An unblinded team member who has no direct interaction with participants will prepare the injections. The participant and the physician administering the injection will remain blinded to treatment allocation. Syringes will be covered with opaque material to maintain blinding.
Blood will be collected before each injection in all participants. For participants assigned to PRP, the blood will be used to prepare the treatment. For the first 10 participants assigned to saline, PRP will also be prepared and analysed to verify the platelet concentration achieved with the preparation procedure. Blood collected from the remaining participants assigned to saline will be discarded.
Participants must discontinue other treatments for erectile dysfunction for four weeks before baseline and until the assessment one month after the last injection. Thereafter, other treatments for erectile dysfunction will be permitted and recorded.
Erectile function and other study outcomes will be assessed at baseline and at 1, 3, 6, and 12 months after the last injection. The primary outcome is the between-group difference in change from baseline in the erectile function domain of the International Index of Erectile Function at one month after the last injection.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A volume of 5 mL PRP will be administered in corpus cavernosum on two occasions, with a 1-month interval between injections
Other: Autologous Platelet Rich Plasma
A volume of 5 mL saline solution will be administered in corpus cavernosum on two occasions, with a 1-month interval between injections.
Other: saline solution (placebo)
A volume of 5 mL PRP will be administered in corpus cavernosum on two occasions, with a 1-month interval between injections
Also known as: PRP, Platelet-Rich Plasma
A volume of 5 mL saline solution will be administered in corpus cavernosum on two occasions, with a 1-month interval between injections.
Also known as: Placebo
Change in IIEF-EF score from baseline to 1 month after the final treatment session
Change in the erectile function (EF) domain score of the International Index of Erectile Function (IIEF) from baseline to 1 month after the final treatment session. The change in IIEF-EF score will be compared between the PRP and saline groups using an intention-to-treat analysis.
Time frame: From baseline to 1 month post the last intervention
Change in IIEF-EF score at 1 month after the final treatment session - per-protocol analysis
Change in the erectile function (EF) domain score of the International Index of Erectile Function (IIEF) from baseline to 1 month after the final treatment session. The change in IIEF-EF score will be compared between the PRP and saline groups using a per-protocol analysis.
Time frame: From baseline to 1 month post the last intervention
Change in IIEF-EF score at 3, 6, and 12 months after the final treatment session
Change in the erectile function (EF) domain score of the International Index of Erectile Function (IIEF) from baseline to 3, 6, and 12 months after the final treatment session. Analyses will be performed using both intention-to-treat and per-protocol populations, comparing the PRP and saline groups.
Time frame: From baseline to 12 months post the last intervention
Analyses of participants achieving a clinically significant improvement in IIEF-EF score at 1, 3, 6, and 12 months
Intention-to-treat and per-protocol analyses of the proportion of participants achieving clinically significant improvements in IIEF-EF at 1, 3, 6, and 12 months following the final treatment session with PRP or saline. Clinically significant improvement is defined according to Rosen et al. as an increase of 2 points for mild ED, 5 points for moderate ED, and 7 points for severe ED
Time frame: From baseline to 12 months post the last intervention
Change in IIEF domain scores at 1, 3, 6, and 12 months
Changes in the remaining domains of the International Index of Erectile Function (IIEF): orgasmic function, sexual desire, intercourse satisfaction, and overall satisfaction. As no minimum clinically important difference has been established for these domains, changes in domain scores will be analysed as continuous variables and compared between the PRP and saline groups.
Time frame: From baseline to 12 months post the last intervention
Participant satisfaction after treatment
Subjective participant satisfaction following treatment, assessed using the Global Satisfaction Question. This analysis will be performed according to the intention-to-treat principle.
Time frame: From baseline to 12 months post last intervention
Use of additional treatments for erectile dysfunction
Use of additional treatments for erectile dysfunction during the study period, including oral medication, intraurethral treatment, intracavernosal injections, vacuum erection devices, and penile implants. The use of additional treatments will be compared between the PRP and saline groups.
Time frame: Until 12 months post last intervention.
Treatment effect according to baseline severity of erectile dysfunction, evaluated by the International Index of Erectile Function-Erectile Function (IIEF-EF)
Subgroup analyses of treatment effects according to severity of erectile dysfunction at baseline (International Index of Erectile Function-Erectile Function (IIEF-EF), recorded just before the first injection). These analyses will be considered exploratory and hypothesis-generating.
Time frame: From baseline to 12 months post last intervention
Adverse events following treatment
Incidence and type of adverse events following PRP and saline injections during the study period. All adverse events will be recorded and described in the final study manuscript.
Time frame: From baseline to 12 months post last intervention
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Aug 2028, 21 months later.
Of 115 non-industry interventional studies with no phase under Erectile Dysfunction, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 52. This study's planned 21 months is below that.
Counting every sponsor, half of 137 studies reached it within 32 months; a quarter within 14 and three quarters within 52.
Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Nov 2026, on Nov 6, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Herlev and Gentofte Hospital